Eichler, Martin ORCID: 0000-0001-9654-2207, Pink, Daniel ORCID: 0000-0001-7243-7373, Menge, Franka, Jakob, Jens, Hentschel, Leopold, Richter, Stephan, Hohenberger, Peter, Kasper, Bernd, Andreou, Dimosthenis, Singer, Susanne, Gruetzmann, Robert, Dmytrow, Diana I., Arndt, Karin, Tuchscherer, Armin, Reichardt, Peter, Ahrens, Marit, Kunitz, Annegret, Mohm, Johannes, Bornhaeuser, Martin, Schmitt, Jochen and Schuler, Markus K. (2021). Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). Eur. J. Cancer Care, 30 (6). HOBOKEN: WILEY. ISSN 1365-2354

Full text not available from this repository.

Abstract

Objective We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST). Methods In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions. Results Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = -15.7), role (B = -25.7), social (B = -18.4), and cognitive functioning (B = -19.7); fatigue (B = 15.93); general health (B = -14.23); and EORTC-sum score (B = -13.82) compared to all other patients. Conclusion The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Eichler, MartinUNSPECIFIEDorcid.org/0000-0001-9654-2207UNSPECIFIED
Pink, DanielUNSPECIFIEDorcid.org/0000-0001-7243-7373UNSPECIFIED
Menge, FrankaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jakob, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hentschel, LeopoldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richter, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hohenberger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kasper, BerndUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Andreou, DimosthenisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Singer, SusanneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gruetzmann, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dmytrow, Diana I.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arndt, KarinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tuchscherer, ArminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reichardt, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ahrens, MaritUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kunitz, AnnegretUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohm, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bornhaeuser, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmitt, JochenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuler, Markus K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-602784
DOI: 10.1111/ecc.13484
Journal or Publication Title: Eur. J. Cancer Care
Volume: 30
Number: 6
Date: 2021
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1365-2354
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
GASTROINTESTINAL STROMAL TUMORS; EORTC QLQ-C30; PREVALENCE; MESYLATE; SARCOMASMultiple languages
Oncology; Health Care Sciences & Services; Nursing; RehabilitationMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60278

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item